(2r,3s)-3-Amino-n-cyclopropyl-2-hydroxyhexanamide | 1053231-20-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2r,3s)-3-Amino-n-cyclopropyl-2-hydroxyhexanamide
• CAS: 1053231-20-1
• 化学式: C₉H₁₈N₂O₂
• 分子量: 186.25
• InChiKey: DRNGSSWBFKDSEE-JGVFFNPUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  75.4
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Inhibitors of Serine Proteases
  申请人：Farmer Luc

  公开号：US20100272681A1

  公开（公告）日：2010-10-28

  The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.

  本发明涉及抑制丝氨酸蛋白酶活性的化合物，特别是针对丙型肝炎病毒NS3-NS4A蛋白酶的活性。这些化合物通过干扰丙型肝炎病毒的生命周期来发挥作用，并且也可用作抗病毒剂。本发明还涉及包含这些化合物的组合物，无论是用于体外使用还是用于治疗患有HCV感染的患者。本发明还涉及通过给患者注射包含本发明化合物的组合物来治疗HCV感染的方法。
• PROCESS FOR THE SYNTHESIS OF TELAPREVIR, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR SOLVATES AS WELL AS INTERMEDIATE PRODUCTS THEREOF
  申请人：SANDOZ AG

  公开号：US20150038677A1

  公开（公告）日：2015-02-05

  The invention relates to a process for the preparation of telaprevir, or a pharmaceutically acceptable salt or solvate thereof, wherein the process requires a smaller number of process steps and/or does not require the use of toxic and instable compounds compared to the known processes. Another embodiment refers to telaprevir, or a pharmaceutically acceptable salt or solvate thereof as well as to intermediate products for preparation of the same, wherein the afore-mentioned products are obtained by the process described herein.

  本发明涉及一种用于制备特拉普雷韦或其药学上可接受的盐或溶剂的工艺，其中该工艺与已知工艺相比需要更少的工艺步骤和/或不需要使用有毒和不稳定的化合物。另一种实施方式涉及特拉普雷韦或其药学上可接受的盐或溶剂，以及用于制备同样的中间产物，其中上述产品通过本文所述的工艺获得。
• PROCESSES AND INTERMEDIATES
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：US20130172276A1

  公开（公告）日：2013-07-04

  The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections.

  本发明涉及化合物和用于制备蛋白酶抑制剂的方法，特别是丝氨酸蛋白酶抑制剂。这些蛋白酶抑制剂对治疗HCV感染非常有用。
• US8399615B2
  申请人：——

  公开号：US8399615B2

  公开（公告）日：2013-03-19
• US8575208B2
  申请人：——

  公开号：US8575208B2

  公开（公告）日：2013-11-05